Synchron
the Stentrode is implanted within the motor cortex via the jugular vein in an endovascular procedure with no craniotomy; Synchron reported positive results from the US COMMAND early-feasibility study and is positioning a 2026 pivotal trial targeting the first FDA commercial approval in motor BCI.
- Country
- United States
- Ticker
- private
Endovascular BCI
FDA IDE trial
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Neurointerfaces & brain–computer interfaces | regenerative-personalized | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.